Skip to main content

Vermillion to Raise $20.5M in Stock Sale Three Months After Disclosing Cash Drought

NEW YORK (GenomeWeb News) — Vermillion, formerly known as Ciphergen Biosystems, today said it plans to gross around $20.5 million in a private stock placement to a group of existing and new investors.
Vermillion said it plans to use the net proceeds from the transaction for general working capital needs.
The investment, expected to close around Aug. 29, would come three months after Vermillion, then still known as Ciphergen, said in a US Securities and Exchange Commission filing that its current cash balances “may not be sufficient to fund planned expenditures."
"This raises substantial doubt about our ability to continue as a going concern," the company said at the time. 
Under the terms of the private placement announced today, Vermillion will sell approximately 24.4 million shares of its common stock and issue warrants for around 19.5 million additional shares with an exercise price of $0.925 per share, the company said.
Earlier this week, the company changed its name to Vermillion and said it expects to begin trading on the Nasdaq exchange Aug. 27 under the ticker symbol VRML.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.